caseism

Abiomed and the AbioCor Clinical Trials (B) Case Solution & Answer

In late 2002, a sensational article in the New York Times describes the experience of the death of James Quinn after implantation of artificial heart AbioCor Abiomed raises questions about the treatment of informed consent in relation to their clinical trials. At the same time, investor confidence in the company is reduced due to the apparent position in the progress of the clinical trial. This case illustrates the B Abiomed handling of the situation, with comments from viewers, including those who are close to the Quinn case, and medical ethicists and investors and financial analysts. An analysis of the choice of Abiomed shows the apparent strategy of the company as one of minimizing the importance of the Times article and reinforce his message to investors to protect the fall in company stock. The case of B also shows how society has changed in 30 days “quiet period”, which became a lightning rod in the media.
by
Elizabeth A. Powell,
Rebecca O. Goldberg
Source: Darden School of Business
6 pages.
Date Posted: January 25, 2010. Prod #: UV4247-PDF-ENG
Abiomed AbioCor clinical trials and (B) Case Solution

Share This

LOOK FOR A FREE CASE STUDY SOLUTION

JUST REGISTER NOW AND GET 50% OFF ON EACH CASE STUDY